Baylor College of Medicine-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2024

  1. Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study

    Pediatrics, Vol. 153, Núm. 3

2023

  1. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727

2022

  1. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e627-e637

  2. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

    New England Journal of Medicine, Vol. 386, Núm. 1, pp. 35-46

2021

  1. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

    New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543

2019

  1. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

    The Lancet HIV, Vol. 6, Núm. 9, pp. e623-e631

2017

  1. Bone and Joint Infections

    Pediatric Infectious Disease Journal, Vol. 36, Núm. 8, pp. 788-799